These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35762321)

  • 1. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.
    Ridker PM; Rifai N; MacFadyen J; Glynn RJ; Jiao L; Steg PG; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Mason RP; Bhatt DL
    Circulation; 2022 Aug; 146(5):372-379. PubMed ID: 35762321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy".
    Sherratt SCR
    Circulation; 2022 Nov; 146(20):e282-e283. PubMed ID: 36374970
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Lakshmanan et al Regarding Article "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy".
    Lakshmanan S; Budoff MJ; Nelson JR
    Circulation; 2022 Nov; 146(20):e284-e285. PubMed ID: 36374969
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
    Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
    Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
    Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
    Szarek M; Bhatt DL; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Mason RP; Ketchum SB; Lira Pineda A; Doyle RT; Steg PG;
    J Am Coll Cardiol; 2024 Apr; 83(16):1529-1539. PubMed ID: 38530686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA
    Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    Circulation; 2021 Jan; 143(1):33-44. PubMed ID: 33148016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
    Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    J Am Heart Assoc; 2022 Mar; 11(6):e022937. PubMed ID: 35261279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
    Bhatt DL; Miller M; Brinton EA; Jacobson TA; Steg PG; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Olshansky B; Chung MK; Gibson CM; Giugliano RP; Budoff MJ; Ballantyne CM;
    Circulation; 2020 Feb; 141(5):367-375. PubMed ID: 31707829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
    Bays HE; Ballantyne CM; Braeckman RA; Stirtan WG; Soni PN
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):37-46. PubMed ID: 23325450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
    Verma S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Dhingra NK; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Mason RP; Tardif JC; Ballantyne CM;
    Circulation; 2021 Dec; 144(23):1845-1855. PubMed ID: 34710343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.